Development of opioid tolerance and dependence hinders the use of opioids for the treatment of chronic pain. In searching for the mechanism and potential intervention for opioid tolerance and dependence, we studied the action of two positive allosteric modulators of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR PAMs). In mice treated with morphine (100 mg/kg, s.c.), acute morphine tolerance and dependence developed in 4e6 h. Treatment with aniracetam, a wellestablished AMPAR PAM, was able to completely prevent and reverse the development of acute antinociceptive tolerance to morphine. Partial, but significant, effects of aniracetam on acute morphine induced-physical dependence were also observed. Moreover, aniracetam significantly reversed the established morphine tolerance and dependence in a chronic model of morphine tolerance and dependence produced by intermittent morphine (10 mg/kg, s.c. for 5d). In addition, HJC0122, a new AMPAR PAM was found to have similar effects as aniracetam but with a higher potency. These previously undisclosed actions of AMPAR PAMs are intriguing and may shed lights on understanding the APMA signaling pathway in opioid addiction. Moreover, these data suggest that AMPAR PAMs may have utility in preventing and treating morphine tolerance and dependence.
Introduction
Opioids remain the most efficacious analgesics for acute ad severe pain. Although opioid analgesics are commonly prescribed for chronic pain treatment, their long-term efficacies are limited by the rapid development of profound antinociceptive tolerance and physical dependence. Needs for dose escalation and complications of drug addiction render the clinical use of opioids in chronic pain to be problematic (Inturrisi, 2002; Jage, 2005) . The molecular mechanisms underlying opioid tolerance and dependence are not fully elucidated.
The AMPA receptors are members of the ligand-gated ionotropic glutamatergic receptor family, playing a critical role in mediating fast excitatory synaptic transmission in the mammalian central nervous system (Song and Huganir, 2002) . The AMPA receptors are tetrameric assemblies of subunits GluR1-4 as two identical heterodimers, in which, GluR2 subunit is essential for the permeability of receptors to Ca 2þ (Hollmann et al., 1991; Hume et al., 1991) .
Growing evidence suggests that regulation of the AMPA receptor is a critical component in the expression of postsynaptic forms of long-term potentiation and long-term depression, as well as homeostatic synaptic plasticity of excitatory synapses (Turrigiano, 2008; Lee and Kirkwood, 2011) . It has been reported that AMPA receptor antagonists LY293558 and LY300168 suppressed morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal (Rasmussen et al., 1996; Rasmussen and Vandergriff, 2003) . It was also reported that LY293558 attenuated analgesic tolerance to morphine, acute, but not chronic, morphine dependence produced by morphine pellet implantation McLemore et al., 1997) . Some of the AMPA receptor antagonistic effect on antinociceptive tolerance may be due to their direct antinociceptive action as ACEA2085 potentiated morphine antinociception in response to an acute thermal stimulus (Nishiyama et al., 1998) . Furthermore, mice deficient in AMPA GluR1 subunit showed reduced tolerance and less severe physical dependence (Vekovischeva et al., 2001; Aitta-aho et al., 2012) . Additionally, a series of NMDA receptor antagonists with some effect on AMPA receptor have been tested to be potent analgesics and blocked morphine tolerance (Lutfy et al., 1997 (Lutfy et al., , 1999 , although blocking the NMDA receptors is known to block opioid tolerance.
More recently, another group of AMPA receptor modulators, the AMPA receptor positive allosteric modulators (AMPAR PAMs) has been developed to allosterically modulate AMPA receptor transmission (Reuillon et al., 2016) . AMPAR PAMs are able to decrease receptor desensitization and/or deactivation and increase the magnitude and kinetics of AMPA receptor-mediated synaptic currents (Lynch, 2006; Arai and Kessler, 2007; Jardemark et al., 2012) . Aniracetam, a clinically used AMPAR PAM as a cognition-enhancing drug, has been shown to selectively inhibit the spontaneous rapid desensitization of AMPA receptors (Lawrence et al., 2003; Vaglenova et al., 2008) . HJC0122, a newly synthesized AMPAR PAM, was shown to display more potent effects as a neuroprotective agent to prevent neuroapoptosis (Chen et al., 2013) . AMPAR PAMs have been shown to improve both positive and negative symptoms as well as cognitive impairment in schizophrenia (Tuominen et al., 2005; Jardemark et al., 2012) and enhance memory in Huntington's disease (Simmons et al., 2009) . Limited studies showed that AMPAR PAMs do not alter pain threshold or acute opioid analgesia (Ren et al., 2009; Oertel et al., 2010) . AMPAkines CX546 and CX516, which are AMPAR PAMs, have been shown to attenuate hyperalgesia induced by spared nerve injury (SNI) and complete Freund's Adjuvant (CFA) in the rat (Le et al., 2014) .
No study, however, has investigated whether AMPAR PAMs are able to modulate the development or expression of morphine tolerance and/or dependence. In this study, we examined the effects of aniracetam and HJC0122 on antinociceptive tolerance to and physical dependence on morphine in two mouse models.
Materials and methods

Materials
Morphine sulfate and naloxone were purchased from Hospira (Lake Forest, IL). HJC0122 ((2R)-Propane-2-sulfonic acid (2-{4-[2-(pyrrolidine-1-carbonyl)pyridin-4-yl]-phenyl}propyl) amide) were synthesized according to previously described (Chen et al., 2013) . Other chemical reagents were obtained from Sigma (St. Louis, MO).
Animals
Male ICR mice (20e25 g, Harlan, Indianapolis, IN) were housed on a 14/10 h light/dark cycle (5:00AM on/7:00PM off) with access to food and water ad libitum. All experiments were performed in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals after approval by the Animal Care and Use Committee of the University of Illinois.
Antinociception test
The tail-flick test was performed to assess basal nociception and morphine-induced antinociception as previously described Hu et al., 2015) . In brief, the distal one-third of mouse tail was immersed into a water bath maintained at 52 C. The latency to a quick tail-flick response was recorded. Unless otherwise stated, morphine-induced antinociception was determined 30 min after the injection of morphine (10 mg/kg, s.c.) and expressed as the percentage of maximal possible effect (MPE) according to the following formula: %MPE ¼ 100*(postdrug latencypredrug latency)/(cut off-predrug latency). A cut-off time of 12 s was applied to prevent tissue damage.
Acute morphine tolerance and dependence
Mice were made acutely tolerant to and dependent on morphine with a high dose of the drug (100 mg/kg s.c., time ¼ 0) according to previous reports (Wang et al., 1999; Shen et al., 2013) . Control mice received to an equal volume of vehicle. To assess tolerance to morphine, mice received test doses of morphine (10 mg/kg, s.c.) 4.5 h later and the antinociceptive effect was measured at 5 h. The presence of tolerance to morphine was demonstrated by a significant reduction of morphineantinociceptive effect. Dependence to morphine was studied by naloxone-precipitated withdraw jumping. These same mice were treated with naloxone (10 mg/kg i.p.) at 5 h and were immediately placed inside glass cylinders. Mice were observed for 15 min with the number of vertical jumps recorded. To prevent the development of morphine tolerance and dependence, AMPAR PAM aniracetam (5e50 mg/kg, i.p.) or HJC0122 (1, 10 mg/kg, i.p.) was given 30 min before the induction dose of morphine (100 mg/kg, s.c., time ¼ À30 min). To reverse the established acute morphine tolerance and dependence, aniracetam (5e50 mg/kg, i.p.) or HJC0122 (1, 10 mg/kg, i.p.) was given 30min before the test dose of morphine (10 mg/kg, s.c.) or naloxone.
Rotarod test
To exclude the possibility of locomotor impairment by aniracetam or HJC0122, a rotarod test was conducted as described previously (Chen et al., 2010; Yang et al., 2011) . The rotarod apparatus (Model series 8; IITC, Woodland Hills, CA) consists of a 1.25 inch-diameter rod powered by a motor with adjustable speeds, subdivided into five compartments. Mice were trained 24h prior by remaining on rotarod at a fixed speed (4 rpm) for 60s. On the day of experiment, mice were retrained at the same speed and those that are unable to hold onto the rotarod for 60s or longer were excluded from further studies. Baseline was obtained 30min later by recording the latency of each mouse to fall off an accelerating rotarod (4e40 rpm over 300s). Mice were then treated with aniracetam (50 mg/kg, i.p.) or vehicle and retested on the accelerating rotarod (4e40 rpm over 300s) 0.5, 1, 2, 4 and 8 h later with a cut-off of 300s.
Chronic morphine tolerance and dependence
Groups of mice were treated with morphine (10 mg/kg, s.c.) or equal volume of vehicle twice a day for 5 days to induce chronic morphine tolerance and dependence (Yang et al., 2011) . Morphine antinociception and tolerance was determined with a test dose of morphine (10 mg/kg, s.c.) on Day 6. On the same day, morphine dependence was examined by recording the number of withdrawal jumps precipitated by naloxone (10 mg/kg, i.p.). Aniracetam was administered 30 min before the test dose of morphine.
Data and statistical analysis
All data are presented as the mean ± S.E.M. Comparisons between treatment groups were analyzed using a one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. Statistical significance was established at the 95% confidence limit.
Results
Aniracetam prevents the development of acute morphine tolerance
The effect of aniracetam on morphine tolerance and dependence was first assessed in mice. Aniracetam is an AMPAR PAM that is clinically used for cognition-enhancing, with well-established AMPA-potentiation properties. To induce morphine tolerance and dependence, mice received a large dose of morphine (100 mg/kg, s.c.). After 4.5 h, morphine-treated mice exhibited a significant reduction of antinociception (16.7 ± 5.1 %MPE v.s. 95.4 ± 2.8 %MPE in vehicle-pretreated mice, p < 0.001, Fig. 1A ) produced by a test dose of morphine (10 mg/kg s.c.), indicative of the development of morphine antinociceptive tolerance. In the mice pretreated with aniracetam (50 mg/kg, i.p.) 30 min before the injection of morphine (100 mg/kg s.c.), morphine-antinociception tolerance was absent (86.1 ± 4.9 %MPE, p < 0.001 v.s. morphine alone, n.s. v.s. vehicle, Fig. 1A ). Pretreatment with aniracetam at a lower dose (16 mg/kg i.p.) was able to partially prevent morphine tolerance (63.5 ± 9.4 % MPE, p < 0.001 v.s. morphine alone, Fig. 1A ). Aniracetam at the lowest dose used (5 mg/kg, i.p.) was ineffective (29.7 ± 11.1 %MPE, Fig. 1A ). These data suggested that aniracetam prevented the development of acute morphine antinociceptive tolerance in a dose-dependent pattern, with an estimated EC 50 around 13.0 mg/ kg.
Aniracetam's effects on acute morphine dependence were tested by naloxone-precipitated withdrawal jumping. Mice were given naloxone (10 mg/kg, i.p.) 5 h after the initial morphine (100mg/kg) treatment, and the jumps were counted for 15 min. Morphine physical dependence was established in mice with the large dose of morphine treatment, which produced significantly more jumps than mice treated with vehicle (84.6 ± 5.7 v.s. 22.0 ± 8.2, p < 0.05, Fig. 1A ). Pretreatment with Aniracetam (50 mg/ kg, i.p.) only partially reduced the naloxone-precipitated jumps compared with morphine dependent mice pretreated with vehicle (53.0 ± 15.2, Fig. 1A ). Aniracetam at lower doses (16, 5 mg/kg, i.p.) showed no effect on preventing the development of morphine dependence (Fig. 1A) . Taken together, we demonstrated that aniracetam prevented acute morphine tolerance and partially reduced acute morphine dependence.
Aniracetam did not affect basal nociception, morphine antinociception, or impair locomotion
To rule out the possibility that aniracetam produced antinociception by itself or interfered with the antinociception induced by morphine, we tested the effect of aniracetam on basal nociception and morphine antinociception. Different groups of mice received aniracetam (50 mg/kg, 100 mg/kg, i.p.) alone, or followed by the administration of morphine (1, 3, or 10 mg/kg, s.c.). Aniracetam at either dose did not affect basal nociception ( Fig. 2A) or morphine-induced antinociception (Fig. 2B) .
Another potential confounding factor in data interpretation was that aniracetam might cause locomotor impairment in mice. To account for this possibility, we further tested the effect of aniracetam on locomotor coordination in a rotarod test. Aniracetam (50, 100 mg/kg, i.p.) did not affect locomotor coordination in the rotarod test (Fig. 2C) . These data suggested that the effect of Aniracetam at doses of up to 100 mg/kg on morphine tolerance and dependence was not attributed to altering basal nociception, interfering with morphine antinociception or impairing locomotion.
Aniracetam reversed acute morphine tolerance and partially blocked dependence
Given the preventive effect of aniracetam on acute morphine tolerance and dependence, we next investigated whether it can reverse the already established acute morphine tolerance and dependence. Mice treated with a large dose of morphine (100 mg/ kg, s.c.) were treated with aniracetam (5, 16, 50 mg/kg, i.p.) 30 min before the testing dose of morphine (10 mg/kg, s.c.) or naloxone (10 mg/kg, i.p.). Aniracetam at the largest dose (50 mg/kg, i.p.) completely restored the antinociceptive effect of morphine (57.1 ± 12.6 %MPE, p < 0.01 v.s. morphine alone, Fig. 3A) . At a lower dose, aniracetam produced partial effect on reducing the established acute morphine tolerance (40.8 ± 10.7 %MPE, Fig. 3A) , and aniracetam at the lowest dose showed no effect (14.1 ± 1.8 %MPE, Fig. 3A) . The EC 50 of aniracetam reversing acute morphine tolerance is estimated to be 43.8 mg/kg. For the established morphine physical dependence, aniracetam produced a partial effect at all doses (Fig. 3B) . These results indicated that aniracetam is dosedependently effective in reversing the acute morphine tolerance, and has a partial effect in reducing the acute morphine dependence.
Reversal of chronic morphine tolerance and dependence by aniracetam
To confirm our observation with aniracetam in acute morphine tolerance and dependence, we used a chronic model to test the effect of aniracetam. Mice received morphine (10 mg/kg, s.c.) twice a day for five days. Prolonged treatment of morphine significantly reduced anti-nociceptive effect of a test dose of morphine (10 mg/ kg, s.c.) given on Day 6 (24.2 ± 8.9 %MPE v.s. 91.4 ± 5.6 %MPE, p < 0.001, Fig. 4A ), and also produced physical dependence as indicated by the naloxone precipitated withdrawal jumps (68.6 ± 9.0 v.s. 24.5 ± 6.0, p < 0.01, Fig. 4B ). Aniracetam (10, 50, 100 mg/kg, i.p.) were given 30 min before the test dose of morphine on Day 6. Larger doses of aniracetam (50, 100 mg/kg, i.p.) significantly restored the anti-nociception produced by the test dose of morphine (65.5 ± 13.0 %MPE, p < 0.05 and and 77.8 ± 10.3 %MPE, p < 0.01 v.s. morphine alone, respectively, Fig. 4A ), which showed the reversal of established chronic morphine tolerance with an estimated EC 50 of 24.2 mg/kg. Also, aniracetam at a dose of 100 mg/ kg (i.p.) significantly decreased the withdraw jumps precipitated by naloxone (21.1 ± 7.6, p < 0.001 v.s. morphine alone, Fig. 4B ), indicating blockade of physical dependence. Here our results indicated that aniracetam reversed the established morphine tolerance and dependence produced by chronic exposure of morphine.
HJC0122 attenuated acute morphine tolerance and dependence
To further validate the effect of AMPAR PAMs in morphine tolerance and dependence, we studied the effect of HJC0122, a new generation and more potent AMPAR PAM (Chen et al., 2013) on morphine tolerance and dependence. Groups of mice were pretreated with HJC0122 (1, 10 mg/kg) 30 min before induction dose of morphine (100 mg/kg). Pretreatment with HJC0122 at both doses of 1 and 10 mg/kg prevented the development of morphine antinociceptive tolerance (51.0 ± 4.9 %MPE by HJC0122 at 1 mg/kg, p < 0.001; 79.1 ± 9.0 %MPE by HJC0122 at 10 mg/kg, p < 0.001 v.s. 24.0 ± 2.82 %MPE morphine alone, Fig. 5A ). Mice pretreated with HJC0122 also showed significantly reduced naloxone-precipitated withdrawal jumps (55.8 ± 8.5 by HJC0122 at 1 mg/kg, p < 0.001; 59.1 ± 6.7 by HJC0122 at 10 mg/kg, p < 0.001, v.s. 108.3 ± 5.6 morphine alone, Fig. 5C ).
When the mice were treated with HJC0122 acutely 30 min before the testing dose of morphine, HJC0122 at 10 mg/kg completely restored the antinociceptive effect of morphine in mice with acute morphine tolerance (84.1 ± 7.6 %MPE, p < 0.001 v.s. morphine alone, Fig. 5B ), and also significantly decreased the naloxone-precipitated withdrawal jumps (52.5 ± 7.1, p < 0.001 v.s. morphine alone, Fig. 5D ). We found that HJC0122 not only prevented the development (Fig. 5A and C) , but also reversed the established acute morphine tolerance and dependence ( Fig. 5B and  D) . The estimated EC 50 of preventing and reversing acute morphine tolerance for HJC0122 is 1.2 mg/kg and 2.2 mg/kg, respectively, which are about 10e20 fold lower than both of aniracetam at 13.0 mg/kg and 43.8 mg/kg.
To rule out the possibility that HJC0122 produced antinociception by itself or interfered with the antinociception induced by morphine, we tested the effect of HJC0122 on basal nociception T im e a fte r tre a tm e n t (h ) T a il flic k la te n c y (s ) T im e a fte r tre a tm e n t (h ) la te n c y to fa ll (s ) and morphine antinociception. HJC0122 (20 mg/kg i.p.) did not affect basal nociception ( Fig. 2A) or alter morphine-induced antinociception (Fig. 2B) . Another confounding factor in data interpretation was that HJC0122 impaired locomotor. However, HJC0122 (20 mg/kg, i.p.) did not affect locomotor coordination in the rotarod test (Fig. 2C) . Taken together, our results suggest that AMPAR PAMs in general have effects in reducing morphine tolerance and dependence.
HJC0122 attenuated chronic morphine tolerance and dependence
To further test the effect of HJC0122 in chronic morphine tolerance and dependence, we employed the chronic mice model of morphine tolerance and dependence developed as described above. Mice received morphine (10 mg/kg, s.c.) twice a day for five days to induce tolerance to morphine (Fig. 6A) . HJC0122 was administered 30 min before the test dose of morphine on Day 6. At the dose of 20 mg/kg, HJC0122 significantly increased the antinociceptive effect produced by morphine (10 mg/kg, s.c.) and partially restore tolerance to morphine (43.9 ± 17.4 %MPE v.s.14.2 ± 5.7 %MPE in vehicle treated group, p < 0.001, Fig. 6A ). Moreover, HJC0122 completely blocked opioid dependence, as it diminished the number of naloxone precipitated withdraw jumps (21. 22 ± 8.2 v.s. 82.8 ± 15.7 in vehicle treated group, p < 0.001, Fig. 6B ). These results suggested that HJC0122 (20 mg/kg) partially attenuated apparent chronic morphine tolerance and fully blocked chronic morphine dependence.
Discussion
In this study, we investigated the role of AMPAR PAMs in opioid tolerance and dependence. We found that aniracetam, a wellstudied AMPAR PAM, and HJC0122, a newer PAM, attenuated morphine antinociceptive tolerance and physical dependence in two mouse models of opioid tolerance and dependence.
Development of tolerance and dependence lowered the efficacy of opioid treatment in patients with chronic pain. The effects of AMPAR PAM on opioid tolerance and dependence have not been investigated before. Both aniracetam and HJC0122, tested in this study effectively prevented and also reversed the development of morphine acute and chronic tolerance and dependence in mice. The newer compound, HJC0122, with an effective dose of 10 mg/kg is more potent than aniracetam with a dose range of 50e100 mg/kg. A few previous studies have showed that AMPAR PAMs do not interfere with the threshold of acute pain (Ren et al., 2009; Oertel et al., 2010) . Our results indicated that aniracetam did not alter basal nociception or acute morphine antinociception. Importantly, aniracetam or HJC0122 did not impair motor coordination in mice, so their effects in the tail-flick assay (prolonged response time) and withdrawal jumping (reduced number of jumps) assays were not due to locomotor impairment.
Previous studies reported that AMPA receptor antagonists could attenuate morphine tolerance and dependence McLemore et al., 1997) . Considering that AMPAR PAM is expected to bind to AMPAR in an allosteric site to reduce the receptor deactivation kinetics and desensitization, the effect of these compounds on morphine tolerance and dependence is interestingly paradoxical. However, it is possible to be explained by their actions on AMPA receptors in descending pain inhibitory circuits. The AMPA receptors constitute the periaqueductal gray-rostral ventromedial medulla (PAG-RVM) descending inhibitory pathway (van Praag and Frenk, 1990; Spinella et al., 1996) . In PAG-RVMspinal descending pathway, a well-known circuit for pain regulation (Fields et al., 1976; Basbaum and Fields, 1984; Heinricher et al., 2009) , PAG neurons form glutamatergic projections through AMPA receptors on GABAergic cells in the RVM and lead to inhibition of dorsal horn neurons (Morgan et al., 2008) . AMPA receptor signaling ensures the intact PAG-RVM-descending pathway (Guan et al., 2002) . Nucleus accumbens (NAc)-RVM circuit, which provides pain-induced analgesia, is another pain modulatory pathway through AMPA receptor signaling (Gear et al., 1999; GhalandariShamami et al., 2011) . Recently, AMPAR PAMs have been shown to produce anti-hyperalgesic effects in both CFA inflammatory and SNI neuropathic pain models in rats (Le et al., 2014) . Another recent study found that local delivery of AMPAR PAMs in NAc provided pain-relieving effects in a paw incision model of acute postoperative pain in rats (Su et al., 2016) . This anti-hyperalgesic effect Groups of eight mice were treated with morphine (10 mg/kg, s.c.) twice a day for 5 days to produce chronic morphine tolerance and dependence. Control group mice received equal numbers and volume of vehicle injections. Morphine tolerance and dependence were assessed on day 6 using the method described above. Aniracetam (10, 50, 100 mg/kg, i.p.) were given acutely to mice 30 min before the test dose of morphine on day 6. (A) Aniracetam dose-dependently restored morphine antinociception and reduced morphine tolerance. EC 50 was estimated from the dose response curve. (B) Aniracetam at dose of 100 mg/kg significantly reduced naloxoneprecipitated withdraw jumps and blocked morphine dependence. Data are expressed as the mean ± S.E.M. **P < 0.01; ***P < 0.001 compared with vehicle group; #P < 0.05; ##P < 0.01; ###P < 0.001 compared with morphine alone group.
of AMPA PAMs may result from potentiation of AMPA receptors signaling in these descending pain inhibitory circuits. On the other hand, pronociceptive effects and increased morphine tolerance and dependence may occur when transmission through AMPA receptors is enhanced in neurons in the anterior cingulate cortex (ACC) , amygdala (Li and Neugebauer, 2004) and spinal dorsal horn (Hartmann et al., 2004) . Increasing evidence suggests that excessive transmission through glutamate receptors including AMPA receptors in the spinal cord contributes to the induction and maintenance of chronic pain (Hartmann et al., 2004; Park et al., 2008) .
Thus, AMPA receptor signaling plays differential roles in morphine tolerance and dependence, depending on the CNS regions involved. In our study, aniracetam and HJC0122 were administered intraperitoneally. The systemically administration of AMPAR PAMs may lead to the actions in the brain, spinal cord or periphery. Our data suggested that AMPAR PAMs in general were effective in reducing morphine tolerance and dependence as a net outcome. The distinct affinity of AMPAR PAMs in different brain regions may also contribute to this net effect. CX546 and CX516, two other AMPAR PAMs, showed region-specific effect on synaptic transmission in the thalamus and the hippocampus (Xia et al., 2005) . CX546 was reported to exhibit high binding affinity within the NAc and brainstem (Montgomery et al., 2009) . To obtain a more comprehensive idea of AMPAR PAMs' effects, further studies are imperative to investigate the binding affinities of these AMPAR PAMs at the different regions in the CNS. Both aniracetam and HJC0122 were effective in attenuating apparent morphine tolerance when tested using 10 mg/kg morphine in the warm water tailflick assay. The assay did not differentiate whether AMPAR PAMs affected the expression of tolerance or reversed it.
Besides opioid tolerance and dependence, another significant risk of opioid treatment is respiratory depression, which is the main casue of deaths due to opioid overdose (Paulozzi et al., 2006; Dahan et al., 2013) . Interestingly, some recent studies reported that AMPAR PAMs could stimulate respiratory rhythmogenesis, but only under the condition of ventilatory suppression, presenting these compounds as ideal drugs to selectively prevent opioid-induced respiratory depression (Ren et al., 2006 (Ren et al., , 2009 Oertel et al., 2010) . The selective counteracting effect of AMPAR PAMs on opioidinduced respiratory suppression was demonstrated in rats (Ren et al., 2006 (Ren et al., , 2009 and was also translated in humans (Oertel et al., 2010) . With minimized risk of respiratory suppression and effects on attenuating the development of tolerance and dependence, AMPAR PAMs can be developed as ideal drugs for the combination use with opioid treatment.
In summary, we reported novel effects of AMPAR PAMs in attenuating morphine tolerance and dependence in two models of morphine tolerance and dependence in mice. Our findings may open a new avenue for preventing morphine tolerance and dependence, treating morphine addiction, and improving pain therapies by reducing morphine tolerance using AMPAR PAMs. With their unique effects on suppressing morphine tolerance, dependence, and stimulating depressed respiration, AMPA receptor positive allosteric modulators have a very promising potential in the management of chronic pain in patients who are tolerant to or dependent on opioid drugs. Groups of mice were developed with chronic morphine tolerance and dependence. HJC0122 (20 mg/kg, i.p.) were given to mice 30min before the test dose of morphine on day 6. (A) HJC0122 effectively increased morphine antinociception and reduced morphine tolerance. (B) HJC0122 significantly reduced naloxone precipitated withdraw jumps and blocked morphine dependence. Data are expressed as the mean ± S.E.M. ***P < 0.001 compared with vehicle group; ###P < 0.001 compared with morphine alone group.
